Your browser doesn't support javascript.
loading
Snake venom disintegrins update: insights about new findings
Almeida, Gabriela de Oliveira; Oliveira, Isadora Sousa de; Arantes, Eliane Candiani; Sampaio, Suely Vilela.
Affiliation
  • Almeida, Gabriela de Oliveira; University of São Paulo. School of Pharmaceutical Sciences of Ribeirão Preto. Department of Clinical Analysis, Toxicology and Food Science. Ribeirão Preto. BR
  • Oliveira, Isadora Sousa de; University of São Paulo. School of Pharmaceutical Sciences of Ribeirão Preto. Department of BioMolecular Sciences. Ribeirão Preto. BR
  • Arantes, Eliane Candiani; University of São Paulo. School of Pharmaceutical Sciences of Ribeirão Preto. Department of BioMolecular Sciences. Ribeirão Preto. BR
  • Sampaio, Suely Vilela; University of São Paulo. School of Pharmaceutical Sciences of Ribeirão Preto. Department of Clinical Analysis, Toxicology and Food Science. Ribeirão Preto. BR
J. venom. anim. toxins incl. trop. dis ; J. venom. anim. toxins incl. trop. dis;29: e20230039, 2023. tab, graf
Article ي En | LILACS, VETINDEX | ID: biblio-1514466
المكتبة المسؤولة: BR68.1
ABSTRACT
Snake venom disintegrins are low molecular weight, non-enzymatic proteins rich in cysteine, present in the venom of snakes from the families Viperidae, Crotalidae, Atractaspididae, Elapidae, and Colubridae. This family of proteins originated in venom through the proteolytic processing of metalloproteinases (SVMPs), which, in turn, evolved from a gene encoding an A Disintegrin And Metalloprotease (ADAM) molecule. Disintegrins have a recognition motif for integrins in their structure, allowing interaction with these transmembrane adhesion receptors and preventing their binding to proteins in the extracellular matrix and other cells. This interaction gives disintegrins their wide range of biological functions, including inhibition of platelet aggregation and antitumor activity. As a result, many studies have been conducted in an attempt to use these natural compounds as a basis for developing therapies for the treatment of various diseases. Furthermore, the FDA has approved Tirofiban and Eptifibatide as antiplatelet compounds, and they are synthesized from the structure of echistatin and barbourin, respectively. In this review, we discuss some of the main functional and structural characteristics of this class of proteins and their potential for therapeutic use.(AU)
الموضوعات
Key words

النص الكامل: 1 الفهرس: LILACS الموضوع الرئيسي: Snake Venoms / Disintegrins اللغة: En مجلة: J. venom. anim. toxins incl. trop. dis موضوع المجلة: TOXICOLOGIA السنة: 2023 نوع: Article

النص الكامل: 1 الفهرس: LILACS الموضوع الرئيسي: Snake Venoms / Disintegrins اللغة: En مجلة: J. venom. anim. toxins incl. trop. dis موضوع المجلة: TOXICOLOGIA السنة: 2023 نوع: Article